Previously, linsitinib has been assessed in vivo to examine the effect on glucose uptake in non-small cell lung carcinoma xenografts, showing that at 60 mg/kg, linsitinib inhibited growth in IGF1R and IR positive tumours [36]. Here, INSR is linked to non-small cell lung carcinoma.